1. Home
  2. VTYX vs NXP Comparison

VTYX vs NXP Comparison

Compare VTYX & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ventyx Biosciences Inc.

VTYX

Ventyx Biosciences Inc.

HOLD

Current Price

$8.17

Market Cap

713.6M

Sector

Health Care

ML Signal

HOLD

Logo Nuveen Select Tax Free Income Portfolio

NXP

Nuveen Select Tax Free Income Portfolio

HOLD

Current Price

$14.25

Market Cap

743.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTYX
NXP
Founded
2018
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
713.6M
743.2M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
VTYX
NXP
Price
$8.17
$14.25
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$14.60
N/A
AVG Volume (30 Days)
1.7M
70.0K
Earning Date
11-06-2025
01-01-0001
Dividend Yield
N/A
4.04%
EPS Growth
N/A
N/A
EPS
N/A
0.54
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$26.81
Revenue Growth
N/A
N/A
52 Week Low
$0.78
$12.91
52 Week High
$10.55
$14.89

Technical Indicators

Market Signals
Indicator
VTYX
NXP
Relative Strength Index (RSI) 47.12 44.76
Support Level $8.39 $14.23
Resistance Level $9.13 $14.38
Average True Range (ATR) 0.63 0.13
MACD -0.25 -0.01
Stochastic Oscillator 20.35 27.00

Price Performance

Historical Comparison
VTYX
NXP

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

About NXP Nuveen Select Tax Free Income Portfolio

Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.

Share on Social Networks: